AbbVie Inc. (ABBV) Competitors & Peers
The 5 largest companies in the same industry as AbbVie Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Competitor | $1,183.46 | P/E 39.7RSI 56Cap 1.06 T |
| JNJ | Competitor | $271.22 | P/E 31.3RSI 55Cap 650.3 B |
| MRK | Competitor | $148.78 | P/E 118.9RSI 58Cap 366.6 B |
| AZN | Peer | $166.58 | P/E 25.2RSI 59Cap 261.4 B |
| NVS | Peer | $145.46 | P/E 21.6RSI 43Cap 272.3 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- MCKSupplier
McKesson is one of AbbVie's three primary U.S. wholesalers that collectively distribute substantially all U.S. pharmaceutical sales (no individual wholesaler exceeds 39% of U.S. gross revenues).
Confirmed — SEC filing / public disclosuresec.gov ↗ - CORSupplier
Cencora is one of AbbVie's three primary U.S. wholesalers that collectively distribute U.S. pharmaceutical sales.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CAHSupplier
Cardinal Health is one of AbbVie's three primary U.S. wholesalers that collectively distribute U.S. pharmaceutical sales.
Confirmed — SEC filing / public disclosuresec.gov ↗ - HALOSupplier
Own 10-K customer-concentration disclosure: AbbVie = 0% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - IRWDSupplier
Own 10-K customer-concentration disclosure: AbbviePlc = 99% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - AMPHSupplier
Own 10-K customer-concentration disclosure: ActavisInc. = 14% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- IRONPartner
Ironwood co-develops and co-markets Linzess globally with AbbVie.
Model-inferred, unverified — treat as a lead, not evidence - AMGNCompetitor
Amgen competes directly with AbbVie in the immunology segment (Amgen Enbrel/Amgevita biosimilar vs AbbVie Humira).
Model-inferred, unverified — treat as a lead, not evidence - JNJCompetitor
J&J competes with AbbVie in the immunology market (Stelara/Tremfya vs Skyrizi).
Model-inferred, unverified — treat as a lead, not evidence - LLYCompetitor
AbbVie competes with Eli Lilly in immunology (Skyrizi vs Taltz in plaque psoriasis/PsA).
Model-inferred, unverified — treat as a lead, not evidence - REGNCompetitor
Regeneron and AbbVie compete in immunology/dermatology — Dupixent (dupilumab, IL-4/13) vs Rinvoq (upadacitinib, JAK) and Skyrizi (risankizumab, IL-23) for atopic dermatitis.
Model-inferred, unverified — treat as a lead, not evidence - ALMCompetitor
ILUVIEN competes with AbbVie's Ozurdex implant for diabetic macular edema.
Model-inferred, unverified — treat as a lead, not evidence - TMOSupplier
Thermo Fisher provides research instruments, mass spectrometers, and contract biomanufacturing services to AbbVie across its immunology and oncology pipelines.
Model-inferred, unverified — treat as a lead, not evidence - GILDCompetitor
Gilead and AbbVie are the two dominant players in HIV treatment globally — Gilead's Biktarvy (BIC/FTC/TAF) vs AbbVie's Kaletra and legacy protease inhibitor regimens.
Model-inferred, unverified — treat as a lead, not evidence - ABVXCompetitor
Abivax's obefazimod competes with AbbVie's Rinvoq in ulcerative colitis.
Model-inferred, unverified — treat as a lead, not evidence - ABTManufacturer
Following the spinoff of AbbVie in 2013, Abbott Laboratories entered into multi-year transition manufacturing and supply agreements to produce pharmaceutical products for AbbVie.
Model-inferred, unverified — treat as a lead, not evidence - ORKACompetitor
Oruka's IL-23 candidates compete with AbbVie's Skyrizi.
Model-inferred, unverified — treat as a lead, not evidence - MRKCompetitor
Merck competes with AbbVie in immunology (Keytruda checkpoint inhibitor vs AbbVie's Rinvoq/Skyrizi in overlapping indications like urothelial cancer/IBD).
Model-inferred, unverified — treat as a lead, not evidence - TEMPUSCustomer
AbbVie licenses Tempus datasets for companion diagnostic and precision medicine R&D.
Model-inferred, unverified — treat as a lead, not evidence - VRTXCompetitor
Vertex and AbbVie compete in pain management — Vertex's Journavx (suzetrigine, Nav1.8 inhibitor) vs AbbVie's pipeline pain assets.
Model-inferred, unverified — treat as a lead, not evidence - CRNXCompetitor
Competes in endocrine pipeline research and hormonal therapies.
Model-inferred, unverified — treat as a lead, not evidence